AMN Healthcare Services (AMN)
(Delayed Data from NYSE)
$41.01 USD
-1.41 (-3.32%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $40.94 -0.07 (-0.17%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$41.01 USD
-1.41 (-3.32%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $40.94 -0.07 (-0.17%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth F Momentum B VGM
Zacks News
Charles River (CRL) Gains From Growing Demand Amid Macro Woes
by Zacks Equity Research
Charles River (CRL) continues to expect that the growth rate will approach 20% in the second half of 2022.
McKesson (MCK) Stock Pares Gains Following Rx Savings Buyout
by Zacks Equity Research
McKesson (MCK) agrees to buy privately-held Rx Savings Solutions in alignment with its strategic plan of creating accessible and affordable treatment options.
Here's Why You Should Retain Stryker (SYK) Stock For Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure weighs on it.
Zimmer Biomet (ZBH) to Offer New Shoulder Replacement System
by Zacks Equity Research
Zimmer Biomet (ZBH) gets FDA nod for the Identity Shoulder System to help surgeons perform anatomic, reverse and revision shoulder replacement with precision.
Abiomed (ABMD) Posts Impellas Positive Study Results in Japan
by Zacks Equity Research
Abiomed's (ABMD) latest multi-center, multi-society study of Impella-supported patients is expected to significantly improve patient outcomes.
3 Reasons to Retain PacBio (PACB) Stock in Your Portfolio
by Zacks Equity Research
PacBio's (PACB) strength in its Sequel system raises optimism about the stock.
4 Stocks With Rising Cash Flows to Survive Market Volatility
by Moumita C. Chattopadhyay
Cash indicates a company's true financial health. It holds the key for its existence, development and success and so AMN, WIRE, TGLS and SP are worth buying.
Here's Why You Should Retain Intuitive Surgical (ISRG) Stock
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to gain traction from the improving adoption of the da Vinci Surgical System. Higher production costs are a woe.
Quest Diagnostics (DGX) to Offer Lab Services for Lee Health
by Zacks Equity Research
Quest Diagnostics (DGX) inked a new agreement to deliver high-quality diagnostics services for a renowned healthcare provider in Southwest Florida.
Here's Why You Should Retain Boston Scientific (BSX) For Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific's (BSX) impressive top-line results and notable acquisitions.
Inari Medical (NARI) Posts Positive Results of FLASH Registry
by Zacks Equity Research
Inari Medical's (NARI) FlowTriever's latest favorable results are expected to significantly improve the treatment of PE.
Neogen (NEOG) Launches Test for Detection of Cashew Allergen
by Zacks Equity Research
Neogen's (NEOG) new quantitative test shows a high level of specificity to very low levels of cashew protein (down to 0.2 ppm).
Exact Sciences (EXAS) Cologuard Business Grows Amid Cost Woes
by Zacks Equity Research
Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is now offering therapy selection tests for patients with advanced cancer.
QIAGEN (QGEN) Assays to Detect Organ Transplant-Related Viruses
by Zacks Equity Research
QIAGEN's (QGEN) latest additions to the NeuMoDx assay menu will help identify EBV and HHV-6 viruses in immunocompromised patients.
3 Reasons to Hold QuidelOrtho (QDEL) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.
Teleflex (TFX) Witnesses Lower UroLift Sales, Cost Woes
by Zacks Equity Research
Teleflex's (TFX) lowered revenue and adjusted EPS outlook for 2022 indicates lackluster performance, which increases investors' concern.
Abiomed's (ABMD) Impella-Related Research Gets FDA Clearance
by Zacks Equity Research
Abiomed's (ABMD) latest regulatory clearances for clinical research of Impella heart pumps in AMI cardiogenic shock patients are expected to significantly improve patient outcomes.
3 Reasons to Hold Catalent (CTLT) Stock in Your Portfolio
by Zacks Equity Research
Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism about the stock.
Cigna's (CI) Arm Adds Five Digital Health Apps to Its Platform
by Zacks Equity Research
Cigna's (CI) unit bolsters its clinical platform Digital Health Formulary by including five on-line solutions, aiming to relieve people from chronic medical conditions.
3 Reasons to Hold Insulet (PODD) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Insulet (PODD) on Omnipod's continued market access expansion.
Here's Why Investors Should Retain Integra (IART) Stock for Now
by Zacks Equity Research
Investors are optimistic about Integra's (IART) better-than-expected results and the continued demand for its products.
Tandem Diabetes (TNDM) Faces Expense Woes, Macro Issues
by Zacks Equity Research
Factoring in the pandemic and competitive pressure as well as evolving economic environment, including inflation and the threat of recession, Tandem Diabetes (TNDM) slashes full-year guidance.
Wall Street Analysts Believe AMN Healthcare (AMN) Could Rally 35%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 34.7% in AMN Healthcare (AMN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
AMN Healthcare Services (AMN) Stock Moves -0.55%: What You Should Know
by Zacks Equity Research
In the latest trading session, AMN Healthcare Services (AMN) closed at $106.05, marking a -0.55% move from the previous day.
LHC Group's (LHCG) Latest Tie-Up to Improve Patient Services
by Zacks Equity Research
LHC Group's (LHCG) latest JV is expected to expand the availability of vital healthcare services to patients in the comfort of their homes.